Jolanda Howe Sells 842 Shares of Mirum Pharmaceuticals (NASDAQ:MIRM) Stock

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) SVP Jolanda Howe sold 842 shares of the firm’s stock in a transaction on Monday, January 26th. The stock was sold at an average price of $96.19, for a total transaction of $80,991.98. Following the completion of the sale, the senior vice president owned 3,700 shares in the company, valued at approximately $355,903. The trade was a 18.54% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link.

Jolanda Howe also recently made the following trade(s):

• On Thursday, January 22nd, Jolanda Howe sold 926 shares of Mirum Pharmaceuticals stock. The stock was sold at an average price of $93.33, for a total value of $86,423.58.

Mirum Pharmaceuticals Price Performance

MIRM traded up $2.35 during midday trading on Tuesday, hitting $99.27. The company had a trading volume of 679,931 shares, compared to its average volume of 877,176. The firm’s 50-day simple moving average is $77.82 and its 200-day simple moving average is $71.21. The company has a market capitalization of $5.10 billion, a PE ratio of -115.43 and a beta of 0.48. Mirum Pharmaceuticals, Inc. has a twelve month low of $36.88 and a twelve month high of $99.44. The company has a debt-to-equity ratio of 1.06, a quick ratio of 3.16 and a current ratio of 3.31.

Mirum Pharmaceuticals (NASDAQ:MIRM) last announced its quarterly earnings results on Tuesday, November 4th. The company reported $0.05 EPS for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.15. The company had revenue of $133.01 million during the quarter, compared to analysts’ expectations of $130.11 million. Mirum Pharmaceuticals had a negative return on equity of 16.47% and a negative net margin of 8.78%.Mirum Pharmaceuticals’s revenue was up 47.1% on a year-over-year basis. During the same period in the prior year, the business posted ($0.30) EPS. Equities research analysts predict that Mirum Pharmaceuticals, Inc. will post -1.43 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

MIRM has been the subject of a number of recent research reports. Morgan Stanley increased their price objective on Mirum Pharmaceuticals from $81.00 to $95.00 and gave the company an “overweight” rating in a report on Tuesday, December 9th. Wall Street Zen upgraded shares of Mirum Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday, January 17th. TD Cowen restated a “buy” rating on shares of Mirum Pharmaceuticals in a research report on Monday, January 12th. Robert W. Baird lifted their price objective on Mirum Pharmaceuticals from $80.00 to $88.00 and gave the stock an “outperform” rating in a research report on Monday, December 8th. Finally, Stifel Nicolaus lifted their price target on Mirum Pharmaceuticals from $92.00 to $98.00 and gave the company a “buy” rating in a research report on Tuesday, December 16th. One research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $104.92.

Mirum Pharmaceuticals News Roundup

Here are the key news stories impacting Mirum Pharmaceuticals this week:

• Positive Sentiment: Large director purchase — Director Patrick J. Heron bought 131,425 shares at ~$68.48 (Jan 23), increasing his ownership ~40%, signaling strong insider conviction. SEC Filing – Heron Form 4
• Positive Sentiment: Price-target upgrade / bullish analyst note — HC Wainwright raised its price target to $130 and kept a Buy rating, issuing a very bullish long‑range EPS view (FY2030 EPS est. $6.16). That upgrade and forecast materially boosts upside expectations. The Fly – HC Wainwright Upgrade
• Positive Sentiment: Acquisition closed — Mirum completed the acquisition of Bluejay Therapeutics, expanding its rare‑disease portfolio and reinforcing growth/synergy narratives that investors favor in biotech M&A. Yahoo Finance – Bluejay Acquisition
• Positive Sentiment: Momentum / new 52‑week high after upgrades — The stock hit a fresh 52‑week high following analyst upgrades and the above news, reinforcing momentum trading and positive sentiment among investors. American Banking News – 52‑Week High
• Negative Sentiment: Executive selling — Several senior executives sold shares on Jan 26 (CEO Christopher Peetz sold 6,831 shares; COO Peter Radovich, CFO Eric Bjerkholt, SVP Jolanda Howe also sold smaller amounts). While transactions appear modest relative to market cap and include routine diversification, they can trigger short‑term selling pressure or worry some investors. SEC filings: CEO CEO Form 4, COO COO Form 4, CFO CFO Form 4, SVP SVP Form 4. Also summarized in a media note on insider selling: American Banking News – Insider Selling

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in Mirum Pharmaceuticals by 22.3% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 14,815 shares of the company’s stock worth $1,170,000 after purchasing an additional 2,700 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its position in Mirum Pharmaceuticals by 377.5% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 9,274 shares of the company’s stock worth $733,000 after acquiring an additional 7,332 shares during the period. Sumitomo Mitsui Trust Group Inc. bought a new stake in shares of Mirum Pharmaceuticals during the 4th quarter worth about $240,000. Wetzel Investment Advisors Inc. acquired a new stake in Mirum Pharmaceuticals in the fourth quarter worth approximately $205,000. Finally, Palumbo Wealth Management LLC boosted its stake in Mirum Pharmaceuticals by 19.8% during the fourth quarter. Palumbo Wealth Management LLC now owns 5,082 shares of the company’s stock valued at $401,000 after buying an additional 840 shares in the last quarter.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.